Last month, Biopharm’s managing director, Andrew Sinclair, and Dr. Yuki Abe headed to Dublin, Ireland, for the Continuous Manufacturing in Biopharmaceuticals conference hosted by Informa Life Sciences.
In conjunction with Jean-Francois Hamel from MIT, the Biopharm team led a pre-conference workshop entitled Implementing a Continuous Manufacturing Process: Key Considerations for a Winning Business Model. The session was filled with lots of lively discussion and sharp insight into continuous processing from the session participants.
The first day of the conference was opened with a powerful keynote speech from Paul Baduel, Director of Global Technology Innovation at Sanofi Pasteur, who shared compelling insight into the continuous manufacturing of vaccines.
The morning continued in great form as Dr. Margit Holzer from Ulysse Consult SARL gave an introduction to the subject by defining continuous processing, and the opening session was concluded by our very own Andrew Sinclair, who focused on evaluating economic impact in his presentation, entitled Continuous Manufacturing: An overview on Cost and Facility. In this session, he discussed how current and future potential can be evaluated by modelling continuous bioprocess operations, and how this allows identification of factors that require optimization and development.
The event continued with a range of excellent speakers who presented their insight and new solutions for a captivated audience. A particular highlight from the second day of the conference, Dr. Roger-Marc Nicoud, founder and former CEO of Novasep, gave an easy to understand yet very thought-provoking talk, entitled Considerations for Designing and Implementing Continuous Processes, which was well received by the conference delegates.
The energy and enthusiasm that permeated the conference was a pleasure to be a part of, and the Biopharm team was glad to be able to share the craic with so many like-minded individuals from the world of bioprocessing.
